Competing interests
Cancer
THOMSEN, CANCER
Dr. Gjertsen reports other from Kinn Therapeutics AS, other from Alden Cancer Therapeutics 2 AS, personal fees from BerGenBio AS, personal fees from Novartis AS, personal fees from Seattle Genetics Inc., personal fees from Pfizer, non-financial support from Roche, non-financial support from MSD, outside the submitted work. Dr. Kalland reports grants from Research Council of Norway, grants from The Norwegian Cancer Society, during the conduct of the study; In addition, Dr. Kalland has a patent PCT/EP2017/077698 pending and is the CEO of and owns Stocks in the Company Alden Cancer Therapy II AS that has sponsored the trial registered at ClinicalTrials.gov Identifier: NCT02423928 and which is published in the presently submitted manuscript. He has received no salary or remuneration from Alden Cancer Therapy II AS. Dr. Øyan owns stocks in the Company Alden Cancer Therapy II AS that has sponsored the trial registered at ClinicalTrials.gov Identifier: NCT02423928 and which is published in the presently submitted manuscript. She has received no salary or remuneration from Alden Cancer Therapy II AS. Dr. Gabriel reports grants from Norwegian Cancer Society during the conduct of the study. Dr Thomsen reports personal fees from Bayer and AstraZeneca, sitting on the advisory board for Eisai Co., and financial support from AstraZeneca to a researcher-initiated trial. Dr Beisland reports personal fees from Pfizer, sitting on advisory boards for BMS and MSD, and having travel expenses covered by Olympus. The remaining authors have no conflicts of interest to report.